Linked Life Data

20137153

Source:http://linkedlifedata.com/resource/pubmed/id/20137153

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-2-8
pubmed:abstractText
At present, most patients with hematological malignancies are treated with conventional chemotherapy, but the relapse frequently occurs in these patients. It is increasingly recognized that the cause of relapse resides in a small portion of the leukemia stem/progenitor cell population which has self-renewal and multilineage differentiation potential. As traditional chemotherapeutic drugs only kill the majority of differentiated tumor cells and hardly affect the tumor stem/progenitor cell, that is why most of the chemotherapies did not achieve good results. In order to completely eradicate hematological malignancies, intrinsic properties of stem/progenitor cells must be studied and only the therapy targeting this population could make tumor curable. Targeting the surface markers which distinguish the tumor stem/progenitor cells from normal stem/progenitor cells, inducing the tumor stem/progenitor cell differentiation, disrupting the signal pathways and niche which regulate the tumor stem/progenitor cell self-renewal are all probable strategies. This review summarizes recent progress of research on leukemia stem/progenitor cell targeting therapy development.
pubmed:language
chi
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1009-2137
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
230-3
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Progress of research on leukemia stem/progenitor cell targeting therapy].
pubmed:affiliation
Department of Hematology, Zhongda Hospital, Southeast University Clinical Medical College, Nanjing 210009, Jiangsu Province, China.
pubmed:publicationType
Journal Article, English Abstract, Review